MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-101027-PIP01-23-M01

Scope of the Application

Active Substance(s)

ANIFROLUMAB

Condition(s)

Treatment of Systemic Lupus Erythematosus

Pharmaceutical Form(s)

Concentrate for solution for infusion, Solution for injection

Route(s) of Administration

INTRAVENOUS USE; SUBCUTANEOUS USE

Name / Corporate name of the PIP applicant

AstraZeneca UK

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, AstraZeneca UK submitted to the licensing authority on 26/05/2023 18:55 BST an application for a Modification

The procedure started on 06/10/2023 14:43 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101027-PIP01-23-M01

Of 25/01/2024 10:07 GMT

On the adopted decision for ANIFROLUMAB (MHRA-101027-PIP01-23-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for ANIFROLUMAB, Concentrate for solution for infusion, Solution for injection , INTRAVENOUS USE; SUBCUTANEOUS USE .

This decision is addressed to AstraZeneca UK, 1 Francis Crick Avenue , Cambridge, UNITED KINGDOM, CB2 0AA

ANNEX I

1. Waiver

1.1 Condition:

Treatment of systemic lupus erythematosus The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 5 years of age. Pharmaceutical form(s): Concentrate for solution for infusion, Solution for injection Route(s) of administration: INTRAVENOUS USE, SUBCUTANEOUS USE Reason for granting waiver: On the grounds the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s)

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of systemic lupus erythematosus

2.2 Indication(s) targeted by the PIP:

Treatment of active, autoantibody-positive patients with systemic lupus erythematosus (SLE) despite receiving standard of care. Treatment of active, autoantibody-positive patients with lupus nephritis (LN) despite receiving standard of care.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 5 years to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Concentrate for solution for infusion Solution for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	4	Study 1 (OBS study #1) Observational study to evaluate the magnitude and distribution of the type I IFN gene signature and additional measures of type I IFN activity in children and adolescents from 5 to less than 18 years of age with pSLE or pLN. Study 2 (pSLE IV study #1) This study was deleted during procedure MHRA-101027-PIP01-23-M01. Study 3 (pSLE + LN IV study #2) Open-label, non-comparative, randomised withdrawal study to evaluate pharmacokinetics, pharmacodynamics, efficacy, safety and tolerability of intravenous anifrolumab in children and adolescents from 5 to less than 18 years of age pSLE and moderate to severe LN based on biopsy-proven proliferative nephritis and UPCR 1. Study 4 (pSLE SC study #3) Open-label, single-arm trial to evaluate pharmacokinetics, pharmacodynamics and safety of subcutaneous anifrolumab in children and adolescents from 5 to less than

		18 years of age with moderate to severely active pSLE. Study 9 (pSLE IV study #1) (This study was added during procedure MHRA-101027-PIP01-23-M01.) Double-blind, placebo-controlled, randomised trial to evaluate pharmacokinetics, efficacy and safety of intravenous anifrolumab in children and adolescents from 5 years to less than 18 years of age with pSLE.
Extrapolation, Modeling & Simulation Studies	4	Study 5 (pSLE IV MS Study #1, pSLE) Modelling and simulation study to project concentration-time profiles of intravenous anifrolumab and gene signature profiles in paediatric SLE patients (with at most mild LN). Study 6 (pSLE SC MS Study #2 pSLE) Modelling and simulation study to project concentration-time profiles of subcutaneous anifrolumab and gene signature profiles in paediatric SLE patients (with at most mild LN). Study 7 (pLN IV MS Study #3 pLN) Modelling and simulation study to project concentration-time profiles of intravenous anifrolumab and gene signature profiles in paediatric SLE patients with moderate to severe LN. Study 8 (Anifrolumab EXP-1 pSLE - SC route of administration) Extrapolation study to evaluate the use of subcutaneous anifrolumab in children from 5 to less than 18 years of age with pSLE.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	30/09/2028
Deferral of one or more studies contained in the paediatric investigation plan:	Yes